Oncoclínicas Stock Crashes 17% Amid Financial Struggles

The Brazilian stock market witnessed a dramatic shift on November 27, 2024. Oncoclínicas, a major player in the healthcare sector, saw its stock (ONCO3) plunge by over 17%.

This sharp decline positioned ONCO3 as the leading loser on the B3 stock exchange. The company’s shares triggered two consecutive trading halts due to reaching the maximum allowed price oscillation.

By 3 PM Brasília time, ONCO3 had settled at an 11% loss after the trading halts. This drop contributed to a staggering year-to-date decline of approximately 80% for the company’s stock.

The broader market also felt the pressure, with the Ibovespa index falling 1.5% on the same day. Oncoclínicas’ financial performance has raised eyebrows among investors and analysts alike.

The company reported a 97.9% year-over-year decrease in net income for the third quarter of 2024. This resulted in a mere R$ 3.1 million ($544,000) in profits.

Rising operational costs have eaten into the company’s margins, with total service costs reaching R$ 1.1 billion ($193 million). Despite these challenges, Oncoclínicas has shown some positive indicators.

Financial Performance and Strategic Shifts

The company reported a 16.6% increase in net revenue for Q3 2024, totaling R$ 1.63 billion ($286 million). It also achieved its first positive free cash flow in several quarters, amounting to R$ 20.3 million ($3.56 million).

Market sentiment remains cautious, however. As of November 26, 2024, Oncoclínicas’ price-to-earnings ratio stood at 27.3x.

Some analysts view this as high given the company’s current financial performance. Investment firms like BTG Pactual and JP Morgan have maintained neutral recommendations on ONCO3 shares.

In response to these challenges, Oncoclínicas has adopted a new growth strategy. The company announced a franchise agreement with Integrare Terapeutica through its subsidiary OC Franquias.

This move will establish a third oncology treatment unit in Fortaleza, Ceará, under a franchise model. Oncoclínicas views this strategy as a way to expand its presence while maintaining financial discipline.

The franchise model doesn’t require capital outlay or working capital commitment from the company. This approach aligns with the principles of self-responsibility and market-driven growth.

In short, the Brazilian healthcare sector, particularly oncology, continues to grow due to increasing demand for cancer treatments.

However, companies in this field face challenges such as rising operational costs and the need for continuous technological investments. Oncoclínicas’ situation reflects these industry-wide trends.

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.